OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Gerds on the Importance of Disease-Modifying Therapies in Myelofibrosis

October 7th 2025

Aaron T. Gerds, MD, MS, discusses the limitations of JAK inhibitors and the objectives that the development of next-generation treatments aim to achieve.

Dr Yee on Daratumumab/Lenalidomide With Ixazomib/Dexamethasone in Multiple Myeloma

October 6th 2025

Andrew Yee, MD, discusses lenalidomide plus ixazomib, dexamethasone, and daratumumab in newly diagnosed multiple myeloma.

Dr Van Tine on Investigating Olaparib Plus Temozolomide vs Investigator’s Choice of Therapy in Advanced Uterine Leiomyosarcoma

October 6th 2025

Brian A. Van Tine, MD, PhD, discusses the use of olaparib plus temozolomide in advanced uterine leiomyosarcoma following progression on chemotherapy.

Dr LeVee on Limitations of the ASCENT-04 Trial of Sacituzumab Govitecan Plus Pembrolizumab in TNBC

October 6th 2025

Alexis LeVee, MD, discusses the clinical implications of the ASCENT-04 trial data for patients with TNBC who relapse following prior PD-1 or PD-L1 therapy.

Dr Runcie on the Mechanism of Action of XmAb30819 in ccRCC

October 6th 2025

Karie Runcie, MD, discusses the mechanism of action of XmAb30819 in clear cell RCC.

Dr Jain on the Role of Ruxolitinib in Polycythemia Vera and Myelofibrosis

October 6th 2025

Akriti G. Jain, MD, discusses the role of ruxolitinib for the treatment with polycythemia vera and myelofibrosis.

Dr Yuan on Intracranial Activity With T-DXd Plus Pertuzumab in HER2+ Metastatic Breast Cancer

October 3rd 2025

Yuan Yuan, MD, PhD, reports the intracranial efficacy of T-DXd plus pertuzumab in HER2-positive breast cancer, per results from the DESTINY-Breast12 study.

Dr Martini on the Mechanism of Action of Cretostimogene Grenadenorepvec in Urothelial Carcinoma

October 3rd 2025

Alberto Martini, MD, discusses cretostimogene grenadenorepvec in urothelial carcinoma.

Dr Visentin on the Relevance of Cost Analysis in Guiding Treatment Sequencing for CLL

October 3rd 2025

Andrea Visentin, MD, discusses the relevance of cost analysis in guiding treatment sequencing for patients with chronic lymphocytic leukemia.

Dr Daver on Persisting Gaps in the Treatment of Relapsed/Refractory Higher-Risk MDS

October 3rd 2025

Naval G. Daver, MD, discusses persisting gaps in the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes.

Dr LeVee on T-DXd in HER2+ Breast Cancer With/Without Brain Metastases

October 3rd 2025

Alexis LeVee, MD, discusses T-DXd in HER2+ breast cancer with or without brain metastases.

Dr Arora on the Declining Incidence of MCL in the United States

October 2nd 2025

Ruby Arora, MD, discusses the declining incidence of MCL in the US, as well as ways to address disparities that remain in MCL management.

Dr Sabari on the FDA Approval of Maintenance Lurbinectedin Plus Atezolizumab for ES-SCLC

October 2nd 2025

Joshua K. Sabari, MD, discusses the significance of the FDA approval of first-line maintenance therapy with lurbinectedin plus atezolizumab for ES-SCLC.

Dr LeVee on Selecting and Sequencing ADCs in Breast Cancer

October 2nd 2025

Alexis LeVee, MD, discusses how clinical trial design guides the practical application of data for ADC selection in breast cancer.

Dr Sweis on Targeting ENPP3 in Clear Cell Renal Cell Carcinoma

October 2nd 2025

Randy F. Sweis, MD, discusses the potential utility of ENPP3 as a therapeutic target in RCC.

Dr Rischin on the Safety of Adjuvant Cemiplimab in High-Risk CSCC

October 1st 2025

Danny Rischin, MD, discusses safety findings from the phase 3 C-POST trial of adjuvant cemiplimab vs placebo in patients with high-risk CSCC.

Dr Olmos on Evaluating HRR Alterations in mHSPC

October 1st 2025

David Olmos, MD, PhD, discusses the evaluation of homologous recombination repair alterations in metastatic hormone-sensitive prostate cancer.

Dr Dahiya on the Unique Mechanism of Action of KITE-363 in LBCL

October 1st 2025

Saurabh Dahiya, MD, FACP, discusses the unique mechanism of action of the CD19/CD20–targeting CAR T-cell therapy in relapsed/refractory LBCL.

Dr Khan on the Evolution of BTK Inhibitors in CLL

October 1st 2025

Cyrus M. Khan, MD, discusses how ibrutinib—a first-generation BTK inhibitor—compares with second-generation BTK inhibitors in CLL.

Dr Yuan on T-DXd in First-Line HER2+ Advanced/Metastatic Breast Cancer

September 30th 2025

Yuan Yuan, MD, PhD, discusses T-DXd plus pertuzumab in first-line HER2-positive advanced/metastatic breast cancer.